Free Trial
NASDAQ:VRAX

Virax Biolabs Group (VRAX) Stock Price, News & Analysis

Virax Biolabs Group logo
$2.04
-0.03 (-1.45%)
(As of 11/1/2024 ET)

About Virax Biolabs Group Stock (NASDAQ:VRAX)

Key Stats

Today's Range
$2.02
$2.17
50-Day Range
$1.53
$5.06
52-Week Range
$0.60
$9.00
Volume
174,595 shs
Average Volume
4.90 million shs
Market Capitalization
$6.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Virax Biolabs Group Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
6th Percentile Overall Score

VRAX MarketRank™: 

Virax Biolabs Group scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Percentage of Shares Shorted

    5.72% of the float of Virax Biolabs Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Virax Biolabs Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Virax Biolabs Group has recently decreased by 9.20%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Virax Biolabs Group does not currently pay a dividend.

  • Dividend Growth

    Virax Biolabs Group does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.72% of the float of Virax Biolabs Group has been sold short.
  • Short Interest Ratio / Days to Cover

    Virax Biolabs Group has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Virax Biolabs Group has recently decreased by 9.20%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 3 people have searched for VRAX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Virax Biolabs Group insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    45.10% of the stock of Virax Biolabs Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 8.61% of the stock of Virax Biolabs Group is held by institutions.

  • Read more about Virax Biolabs Group's insider trading history.
Receive VRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virax Biolabs Group and its competitors with MarketBeat's FREE daily newsletter.

VRAX Stock News Headlines

Virax Biolabs announces distribution agreement with Europa Biosite
Virax Biolabs Expands Reach with Europa Biosite Deal
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Virax Biolabs Group Ltd Class A VRAX
See More Headlines

VRAX Stock Analysis - Frequently Asked Questions

Virax Biolabs Group's stock was trading at $1.46 at the beginning of 2024. Since then, VRAX stock has increased by 39.7% and is now trading at $2.04.
View the best growth stocks for 2024 here
.

Virax Biolabs Group's stock reverse split on the morning of Monday, December 18th 2023. The 1-10 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Virax Biolabs Group (VRAX) raised $7 million in an initial public offering on Thursday, July 21st 2022. The company issued 1,400,000 shares at $5.00 per share. Boustead Securities served as the underwriter for the IPO.

Shares of VRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Virax Biolabs Group investors own include Plug Power (PLUG), GeoVax Labs (GOVX), Fortress Biotech (FBIO), KALA BIO (KALA), Comtech Telecommunications (CMTL), FuelCell Energy (FCEL) and Lipocine (LPCN).

Company Calendar

Today
11/02/2024
Next Earnings (Estimated)
11/19/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VRAX
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$160,000.00
Book Value
$2.00 per share

Miscellaneous

Free Float
1,775,000
Market Cap
$6.59 million
Optionable
Not Optionable
Beta
1.93
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:VRAX) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners